2012 Fiscal Year Final Research Report
Development of immunotherapy against the bone destructive tumor
Project/Area Number |
23659946
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Surgical dentistry
|
Research Institution | The University of Tokushima |
Principal Investigator |
HIASA Masahiro 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 助教 (90511337)
|
Project Period (FY) |
2011 – 2012
|
Keywords | 破骨細胞 / 樹状細胞 / TACE / TIMP3 |
Research Abstract |
Multiple myeloma (MM) generates devastating bone destruction. We recently reported that TNFα converting enzyme (TACE) expression in monocytes cleaved their surface M-CSF receptor (M-CSFR), which drastically disrupts osteoclastogenesis(Blood, 2009). Because TACE activity is inhibited by TIMP3, we explored the role of BMSC-derived TIMP3 in monocytic differentiation into DC or OC in MM. This study clarified that TIMP3 over-produced in MM bone marrow microenvironment restores surface M-CSFR on monocytes to facilitate their downstream signaling, which causes extensive bone destruction and impaired DC differentiation in MM. TIMP3 may therefore become a novel target in the treatment of MM bone disease.
|
Research Products
(12 results)
-
[Journal Article] KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts2012
Author(s)
Hirokazu Miki, Shingen Nakamura, Shuji Ozaki, A Oda, H Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Q Cui, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, A Sakai, Masahiro Abe and Toshio Matsumoto
-
Journal Title
British Journal of Haematology
Volume: Vol.155, No.3
Pages: 328--339
DOI
Peer Reviewed
-
[Journal Article] Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors2012
Author(s)
Akishige Ikegame, Shuji Ozaki, Daisuke Tsuji, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, A Nakano, Kumiko Kagawa, Kyoko Takeuchi, Masahiro Abe, Keiichiro Watanabe, Masahiro Hiasa, N Kimura, Y Kikuchi, A Sakamoto, K Habu, M Endo, K Itoh, H Yamada-Okabe and Toshio Matsumoto
-
Journal Title
DOI
Peer Reviewed
-
[Journal Article] Delayed treatment with vitamin C and N-acetyl-L: -cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.2011
Author(s)
Ayako Nakano, Masahiro Abe, Asuka Oda, Hiroe Amou, Masahiro Hiasa, Shingen Nakamura, Hirokazu Miki, Takeshi Harada, Shirou Fujii, Kumiko Kagawa, Kyoko Takeuchi, Takashi Watanabe, Shuji Ozaki and Toshio Matsumoto
-
Journal Title
International Journal of Hematology
Volume: Vol.93, No.6
Pages: Vol.93, No.6
DOI
Peer Reviewed
-
[Journal Article] Targeting myeloma-osteoclast interaction with V9V2 T cells2011
Author(s)
Qu Cui, Hironobu Shibata, Asuka Oda, Hiroe Amou, Ayako Nakano, Kenichiro Yata, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe
-
Journal Title
International Journal of Hematology
Volume: Vol.94, No.1
Pages: 63-70
DOI
Peer Reviewed
-
[Journal Article] The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells2011
Author(s)
J Asano, A Nakano, A Oda, H Amou, Masahiro Hiasa, Kyoko Takeuchi, H Miki, S Nakamura, T Harada, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Ken-ichiro Yata, A Sakai, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe
-
Journal Title
DOI
Peer Reviewed
-
-
-
-
-
-
-